基于关联规则与熵方法的血脂异常中药复方专利配伍规律研究(1)
[摘要]分析血脂异常中药复方专利配伍规律，为临床研发血脂异常中药新药提供依据。提取1985年9月至2014年3月国家专利数据库中治疗血脂异常的243项中药复方专利，运用中医传承辅助系统(V1.1)中药物频次、关联规则、复杂网络、熵方法分析中药复方专利的配伍规律。提取出治疗血脂异常中药复方专利中最常见的单药有山楂109(44.86%)等;最常见的对药有山楂-丹参53(21.81%)等;最常见的角药配伍有山楂-决明子-何首乌25(10.29%)等;基于关联规则发现常见药物组合有夏枯草→丹参(0.833);大黄，泽泻→何首乌(1.000);丹参，决明子，泽泻→何首乌(0.929)等;基于复杂网络发现的核心药物有：丹参、山楂等;通过熵方法提取出的新方组合有白术、甘草、柏子仁、防己;陈皮、茯苓、薏苡仁、半夏等。研究表明血脂异常中药复方专利是有配伍规律可循的，提示今后研发高效血脂异常中药新药应从以下6方面着手：①单味药应优先选择山楂等;②对药应优先选择山楂-丹参等;③角药应优先选择山楂-决明子-何首乌等;④注重药物之间的配伍关系，关联度高的药物组合应优先选择夏枯草→丹参;大黄，泽泻→何首乌;丹参，决明子，泽泻→何首乌等;⑤以核心治法为主体，运用核心药物，适当配伍如消食泻浊法，核心药物为山楂，可适量配伍丹参等;⑥应用新方白术、甘草、柏子仁、防己;陈皮、茯苓、薏苡仁、半夏等。
, 百拇医药
[关键词]血脂异常;专利;关联规则;复杂网络;熵方法;配伍规律;新药研发
[收稿日期]2014-06-04
[基金项目]国家自然科学基金项目(81202803)
[通信作者]*何庆勇，博士，副主任医师，副教授， Tel：(010)88001381， E-mail：heqingyongg@163.com
[作者简介]尹湘君，硕士研究生，研究方向为中药复方防治心血管疾病，E-mail：yinxiangjun2010@sina.comCompatibility regularity of compound traditional Chinese medicine patents
based on association principle and entropy method
, 百拇医药
YIN Xiang-jun1，2， HE Qing-yong1*
(1.Guang′anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053， China;
2. Beijing University of Chinese Medicine， Beijing 100029， China)
[Absract]To analyze the compatibility regularity of compound traditional Chinese medicine(TCM) patents for treating dyslipidemia， and provide basis for the clinical development and research of new TCM for treating dyslipidemia. Totally 243 compound traditional Chinese medicine patents for treating dyslipidemia were collected from the national patent database from September 1985 to March 2014 and analyzed by using drug frequency， association rules， complex network and entropy method of Traditional Chinese Medicine Inheritance System (V1.1). The commonest single medicine in the treatment of dyslipidemia is Crataegi Fructus 109(44.86%). The commonest pair medicine is Crataegi Fructus-Salviae Miltiorrhizae Radix et Rhizoma 53(21.81%). The commonest corner drug is Crataegi Fructus-Cassiae Semen-Polygoni Multiflori Radix 25(10.29%). The common prescriptions on basis of association rules are Prunellae Spica→Salviae Miltiorrhizae Radix et Rhizoma(0.833)， Rhei Radix et Rhizoma， Alismatis Rhizoma→Polygoni Multiflori Radix(1.00)， Salviae Miltiorrhizae Radix et Rhizoma， Cassiae Semen， Alismatis Rhizoma→Polygoni Multiflori Radix(0.929). The core drugs based on complex networks are Salviae Miltiorrhizae Radix et Rhizoma and Crataegi Fructus. The new prescriptions extracted by entropy method are Atractylodis Macrocephalae Rhizoma-Glycyrrhizae Radix et Rhizoma-Platycladi Semen-Stephaniae Tetrandrae Radix; Citri Reticulatae Pericarpium-Poria-Coicis Semen-Pinelliae Rhizoma. This study shows the regularity in the compatibility of compound TCM patents treating dyslipidemia， suggesting that future studies on new traditional Chinese medicines treating dyslipidemia should focus on the following six aspects： ① Single medicine should be preferred： e.g. Crataegi Fructus; ② Pair medicines should be preferred： e.g. Crataegi Fructus-Salviae Miltiorrhizae Radix et Rhizoma; ③ Corner drugs should be preferred： e.g. Crataegi Fructus， Cassiae Semen， Polygoni Multiflori Radix; ④ The compatibility among drugs shall be given attention， and highly correlated drugs should be preferred： e.g. Prunellae Spica， Salviae Miltiorrhizae Radix et Rhizoma; Rhei Radix et Rhizoma， Alismatis Rhizoma， Polygoni Multiflori Radix; Salviae Miltiorrhizae Radix et Rhizoma， Cassiae Semen， Alismatis Rhizoma， Polygoni Multiflori Radix; ⑤ Core drugs should be dominant and compatible， e.g. in the digestion catharsis method， the core drugs is Crataegi Fructus and compatible with Salviae Miltiorrhizae Radix et Rhizoma; ⑥ Application of new prescriptions： Atractylodis Macrocephalae Rhizoma， Glycyrrhizae Radix et Rhizoma， Platycladi Semen， Stephaniae Tetrandrae Radix; Citri Reticulatae Pericarpium， Poria， Coicis Semen， Pinelliae Rhizoma., 百拇医药(尹湘君 何庆勇)
, 百拇医药
[关键词]血脂异常;专利;关联规则;复杂网络;熵方法;配伍规律;新药研发
[收稿日期]2014-06-04
[基金项目]国家自然科学基金项目(81202803)
[通信作者]*何庆勇，博士，副主任医师，副教授， Tel：(010)88001381， E-mail：heqingyongg@163.com
[作者简介]尹湘君，硕士研究生，研究方向为中药复方防治心血管疾病，E-mail：yinxiangjun2010@sina.comCompatibility regularity of compound traditional Chinese medicine patents
based on association principle and entropy method
, 百拇医药
YIN Xiang-jun1，2， HE Qing-yong1*
(1.Guang′anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053， China;
2. Beijing University of Chinese Medicine， Beijing 100029， China)
[Absract]To analyze the compatibility regularity of compound traditional Chinese medicine(TCM) patents for treating dyslipidemia， and provide basis for the clinical development and research of new TCM for treating dyslipidemia. Totally 243 compound traditional Chinese medicine patents for treating dyslipidemia were collected from the national patent database from September 1985 to March 2014 and analyzed by using drug frequency， association rules， complex network and entropy method of Traditional Chinese Medicine Inheritance System (V1.1). The commonest single medicine in the treatment of dyslipidemia is Crataegi Fructus 109(44.86%). The commonest pair medicine is Crataegi Fructus-Salviae Miltiorrhizae Radix et Rhizoma 53(21.81%). The commonest corner drug is Crataegi Fructus-Cassiae Semen-Polygoni Multiflori Radix 25(10.29%). The common prescriptions on basis of association rules are Prunellae Spica→Salviae Miltiorrhizae Radix et Rhizoma(0.833)， Rhei Radix et Rhizoma， Alismatis Rhizoma→Polygoni Multiflori Radix(1.00)， Salviae Miltiorrhizae Radix et Rhizoma， Cassiae Semen， Alismatis Rhizoma→Polygoni Multiflori Radix(0.929). The core drugs based on complex networks are Salviae Miltiorrhizae Radix et Rhizoma and Crataegi Fructus. The new prescriptions extracted by entropy method are Atractylodis Macrocephalae Rhizoma-Glycyrrhizae Radix et Rhizoma-Platycladi Semen-Stephaniae Tetrandrae Radix; Citri Reticulatae Pericarpium-Poria-Coicis Semen-Pinelliae Rhizoma. This study shows the regularity in the compatibility of compound TCM patents treating dyslipidemia， suggesting that future studies on new traditional Chinese medicines treating dyslipidemia should focus on the following six aspects： ① Single medicine should be preferred： e.g. Crataegi Fructus; ② Pair medicines should be preferred： e.g. Crataegi Fructus-Salviae Miltiorrhizae Radix et Rhizoma; ③ Corner drugs should be preferred： e.g. Crataegi Fructus， Cassiae Semen， Polygoni Multiflori Radix; ④ The compatibility among drugs shall be given attention， and highly correlated drugs should be preferred： e.g. Prunellae Spica， Salviae Miltiorrhizae Radix et Rhizoma; Rhei Radix et Rhizoma， Alismatis Rhizoma， Polygoni Multiflori Radix; Salviae Miltiorrhizae Radix et Rhizoma， Cassiae Semen， Alismatis Rhizoma， Polygoni Multiflori Radix; ⑤ Core drugs should be dominant and compatible， e.g. in the digestion catharsis method， the core drugs is Crataegi Fructus and compatible with Salviae Miltiorrhizae Radix et Rhizoma; ⑥ Application of new prescriptions： Atractylodis Macrocephalae Rhizoma， Glycyrrhizae Radix et Rhizoma， Platycladi Semen， Stephaniae Tetrandrae Radix; Citri Reticulatae Pericarpium， Poria， Coicis Semen， Pinelliae Rhizoma., 百拇医药(尹湘君 何庆勇)